On Friday, an appeals court removed postal access to mifepristone for millions of American women. On Monday, Justice Samuel Alito — who authored the overturning of Roe v. Wade — signed the stay order. A week's reprieve in one of the most pivotal legal battles of the post-Roe era.
Black Friday: Appeals court restricts national access
It all began late Friday afternoon, May 1, 2026. The U.S. Court of Appeals for the Fifth Circuit, based in New Orleans and known for its structural conservatism, issued a 19-page decision written by Judge Stuart Kyle Duncan — appointed by Donald Trump — that upended access to medication abortion nationwide. In essence, the court mandated a return to an older Food and Drug Administration (FDA) regulation requiring a doctor to dispense mifepristone in person to the patient. The result: prescription via telemedicine and postal delivery — which had become the most common access methods since the Covid-19 pandemic — were immediately suspended.
The potential impact is staggering. In 2023, medication abortions accounted for over 60% of all abortions in the United States, according to Guttmacher Institute data. Since the Supreme Court overturned Roe v. Wade in June 2022, the combination of mifepristone and misoprostol prescribed remotely has become the main way for women living in states that have banned surgical abortions to still access them. By the end of 2024, one in four abortions was performed via telemedicine. The Fifth Circuit's decision does not restrict marginal access: it strikes at the heart of the system.
Weekend of Urgency: Two Manufacturers Before the Supreme Court
In a snap, the two mifepristone manufacturers — Danco Laboratories, which markets the brand-name version Mifeprex, and GenBioPro, which produces the generic — filed emergency appeals directly with the Supreme Court on Saturday morning, less than twenty-four hours after the Fifth Circuit's decision. Danco warned that the appellate court's order "injects immediate confusion and disruption into highly time-sensitive medical decisions." GenBioPro described the risk of an "abrupt interruption of access for millions of patients." For thousands of women with appointments scheduled that weekend to receive the medication, uncertainty was total.
Justice Samuel Alito handled the emergency requests from the Fifth Circuit. The irony of history, or rather the relentless logic of American institutions: it was he, the author of the Dobbs v. Jackson Women's Health Organization decision in June 2022 that ended fifty years of constitutional protection for abortion rights, who found himself having to rule urgently on access to the abortion pill. Monday morning, Alito signed an administrative stay order blocking the Fifth Circuit's ruling, maintaining postal and telemedicine access to mifepristone until May 11 at 5:00 PM — giving the Supreme Court time to review the arguments from the various parties, with briefs due before Thursday evening.
Louisiana and State Political Argument
At the origin of this legal challenge: Louisiana, a Gulf state that since 2022 has adopted some of the most restrictive anti-abortion legislation in the country, banning almost all abortions in all forms. The central thesis of the Louisiana lawsuit is that the FDA's federal rules authorizing the remote prescription of mifepristone "undermine" state laws protecting life, and therefore the state is justified in demanding their repeal. Louisiana's Attorney General, Liz Murrill, did not mince words after Alito's order: she denounced the manufacturers as seeking to "kill more babies quickly and efficiently by mail, without medical supervision."
This case is the second act in a legal saga that the Supreme Court already encountered in 2024. At that time, the nine justices had unanimously rejected a first attempt at restriction — but on procedural grounds (lack of standing for the plaintiffs), without ever ruling on the merits. This left the door open for new lawsuits. With Louisiana as a sovereign state plaintiff, the legal configuration is different, and potentially more favorable to restrictions. The Supreme Court's final decision — expected in the coming weeks or months — could be one of the most consequential rulings for American reproductive health since the Dobbs decision itself.
Seven Million Women, a Pill with Established Safety
Meanwhile, the scientific facts remain stable, even if politics is not. Since its FDA approval in 2000, over 7 million American women have used mifepristone. Independent studies — including a CNN analysis comparing the risk profiles of different medications — conclude that its rate of serious complications is lower than that of penicillin or Viagra. The FDA itself requested in January 2026 the suspension of the Louisiana proceedings, wanting to conduct its own safety review, commissioned by Robert F. Kennedy Jr. This review was triggered in response to a report by the conservative think tank Ethics and Public Policy Center claiming a higher complication rate than official data — a report dismissed as "pseudoscience" by the vast majority of reproductive health researchers.
Medical arguments and political arguments do not carry the same weight — and the Supreme Court will have to choose which to heed. Medical professional associations, led by the American College of Obstetricians and Gynecologists, have filed amicus curiae briefs supporting the maintenance of current access. Anti-abortion groups, on the other hand, are capitalizing on what they see as a historic window: with a conservative majority of 6 out of 9 justices on the Supreme Court and a Trump administration aligned with their positions, the political conditions for a victory on the merits have never been more favorable.
Editorial Opinion
What is at stake in this legal battle goes far beyond the issue of mifepristone. It is the question of whether states can use the federal system to circumvent the decisions of the national scientific agency — the FDA — in the name of ideology. The fact that Alito, the author of the overturning of Roe, was forced to sign an order protecting access to abortion is less an irony than a revelation of how American institutions actually function: even the most conservative judges must sometimes contain the momentum they themselves helped to create.
Key Takeaways
- On Friday, the Fifth Circuit removed postal and telemedicine access to mifepristone — blocked on Monday by SCOTUS.
- Justice Alito — author of the overturning of Roe v. Wade — signed the protection order until May 11.
- Over 60% of American abortions are medication abortions; 1 in 4 are done via telemedicine.
- 7 million American women have used mifepristone since 2000 — a safety profile superior to penicillin according to studies.
- The SCOTUS's final decision could permanently redefine abortion access throughout the United States.





